Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

8 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling of human hormone resistant prostate cancer

ABSTRACT: In this study we performed transcriptional profiling of transurethral resections of hormone resistant prostate cancer and compared it with benign prostatic hyperplasia (BPH), untreated localized prostate cancer and hormone sensitive prostate cancer. Experiment Overall Design: Each sample (= Array) is derived from a different patient with the following subsequent disease states: 3x BPH, 7x localized prostate cancer samples, 2 horomone sensitive prostate cancer samples, one locally advanced prostate cancer, 4x hormone resistant prostate cancer early stage and 3x hormone resistant prostate cancer late stage. Experiment Overall Design: Platform was Affymetrix

ORGANISM(S): Homo sapiens

SUBMITTER: Oliver Christoph Stoss

PROVIDER: E-GEOD-5377 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer.

Stoss O O Werther M M Zielinski D D Middel P P Jost N N Rüschoff J J Henkel T T Albers P P

Prostate cancer and prostatic diseases 20070724 2

The molecular mechanisms for hormone-resistant prostate cancer progression still remain elusive, mainly due to the limited availability of corresponding tissue. As transurethral resection (TUR) is a common palliative therapy for patients with hormone refractory prostate cancer (HRPC) who have subvesical obstruction, we aimed to demonstrate that TUR samples can be used to identify significantly affected biological pathways during the switch to HRPC using oligonucleotide microarray analysis. Among ...[more]

PMID: 17646850

Similar Datasets

Gene expression profiling of hormone resistant prostate cancer

Project description:In this study we performed transcriptional profiling of transurethral resections of hormone resistant prostate cancer and compared it with benign prostatic hyperplasia (BPH), untreated localized prostate cancer and hormone sensitive prostate cancer. Keywords: time course; disease state analysis

2007-07-01 | GSE5377 | GEO

Genomic changes of Peripheral Blood Neutrophils throughout Prostate Cancer Progression

Project description:Bulk RNA sequencing of peripheral blood neutrophils from prostate cancer at different stages of disease progression, including localized disease, hormone-sensitive- and castration-resistant metastatic prostate cancer

2023-12-13 | GSE197609 | GEO

Genomic Signatures of Metastasis in Prostate Cancer

Project description:Background: Metastases result in 90% of all cancer deaths. Prostate cancer primary tumors evolve to become metastatic through selective alterations, such as amplification and deletion of genomic DNA. Methods: Genomic DNA copy number alterations were used to develop a gene signature that measured the metastatic potential of a prostate cancer primary tumor. We studied the genomic landscape of these alterations in 294 primary tumors and 49 metastases from 5 independent cohorts. Receiver-operating characteristic cross-validation and Kaplan-Meier survival analysis were performed to assess the accuracy of our predictive model. The signature was measured in a panel of 337 cancer cell lines from 29 different tissue origins. Results: We identified 399 copy number alterations around genes that were over-represented in metastases and predictive of whether a primary tumor will metastasize. Cross-validation analysis resulted in a predictive accuracy of 80.5% and log rank analysis of the metastatic potential score was significantly related to the endpoint of metastasis-free survival (p=0.014). The metastatic signature was observed in cell lines originating from lung, breast, colon, thyroid, rectum, pancreas and melanoma. The signature was comprised in part of genes of known or putative metastatic role — 8 solute carrier genes, 6 Cadherin family genes and 5 potassium channel genes — that function in metabolism, cell-to-cell adhesion and escape from anoikis/apoptosis. Conclusions: Somatic Copy number alterations are an independent predictor of metastatic potential. The data indicate a prognostic utility for using primary tumor genomics to assist in clinical decision making and developing therapeutics for prostate and likely other cancers. genomic DNA from 29 prostate cancer tumors with matched normals run on Affymetrix 6.0 SNP arrays.

2013-12-01 | E-GEOD-27105 | biostudies-arrayexpress

Co-expression of genes with ERG in prostate cancers

Project description:ERG overexpression is the most frequent molecular alteration in prostate cancer. We analyzed different stages of prostate cancer to identify genes that were coexpressed with ERG overexpression. In primary prostate tumors, it was shown that TDRD1 expression was the strongest correlated gene with ERG overexpression and we suggest TDRD1 as a direct ERG target gene. 48 Prostate cancer samples from radical prostatectomies were included in this study. These samples contained more than 70% cancer and less than 30% stromal tissue. Each sample was analyzed once.

2013-02-11 | E-GEOD-41408 | biostudies-arrayexpress

The use of Nitric Oxide as a Radiosensitiser of Hypoxic Prostate Cancer Characterized by Data Independent Label-free Ion Mobility LC-MS

Project description:The use of Nitric Oxide as a Radiosensitiser of Hypoxic Prostate Cancer Characterized by Data Independent Label-free Ion Mobility LC-MS

2020-02-27 | PXD009047 | Pride

Transcriptional differences between the peripheral and the transcription zone of the prostate

Project description:The occurrence of cancer is not equally distributed across the three zones of the prostate gland; the peripheral (PZ), central and transition zones (TZ). The majority (~70%) of diagnosed prostate cancer (PCa) is found in the PZ compared to the TZ. In this study we comprehensively measure whole genome expression by next-generation sequencing of the PZ and TZ from prostate tissue. Our aim was to identify the molecular and metabolic differences between the two zones that could underlie the differential susceptibility to PCa incidence. Following histological assessment of tissue adjacent to the biopsies used for RNAsequencing we identified 4 out of the 18 samples to be cancerous. Although these are included in the ArrayExpress submission, they were not included in the final analysis of data that reported the molecular differences between morphologically normal peripheral and transition zones.

2017-07-04 | E-MTAB-5021 | biostudies-arrayexpress

MicroRNA profiling in primary prostate cancer

Project description:Deregulated expression of miRNAs contributes to prostate cancer progression. This study is aimed to identify which miRNA(S) is (are) asociated with prostate cancer aggressiveness. Prostate cancer tissues and matched adjacent normal tissue were used to isolate total RNA. miRNA expressions were analyzed by miRNA Microarray assay.

2011-12-10 | E-GEOD-34310 | biostudies-arrayexpress

MicroRNA expression data from human prostate cancer

Project description:MicroRNAs are small RNA molecules of about 21-25 nucleotides that regulate gene expression via posttranscriptional inhibition of protein synthesis. They play a vital role in the process of tumorigenesis. To identify and characterize the diagnostic potential of miRNAs in prostate cancer, a leading cause of tumor mortality, we performed microarray based screening of miRNA expression profiles. We selected 20 cases of moderately differentiated prostate cancer and generated pairs of tumor and corresponding normal tissue by microdissection

2010-07-20 | E-GEOD-23022 | biostudies-arrayexpress

Human Prostate and Benign Prostate Hyperplasia, LC MSMS

Project description:It is well known that prostate cancer (PCa) is a progressive disease involving multiple gene alterations. The Gleason score (GS) is a morphologic feature of PCa used in the clinic to evaluate the risk of disease progression. However, GS often fail to clearly distinguish between indolent and aggressive disease. The aim of this study was to identify potential biomarkers for PCa risk stratification. An in-depth proteomics analysis (LC ESI-MS/MS) was performed on human PCa and BPH tissues. First, we identified differentially expressed proteins between PCa and BPH samples. We then filtered the proteins based on peptide spectrum matches and selected a panel of candidates. To assess and validate the clinical significance of these peptides we performed an integrative bioinformatics analysis using public database repositories. We identified YWHAZ, an androgen receptor downstream target, as one of the proteins enriched in PCa compared with BPH. We also found a strong association of YWHAZ expression with poor prognosis across different PCa datasets. Briefly, overall and relapse-free survival were significantly shorter in PCa cases expressing high vs. low YWHAZ expression. Further, multivariate analyses displayed high significant correlation with poor prognosis, independent from GS, age, PSA at diagnosis and TMPRSS2-ERG fusion. A multi-cancer screening for YWHAZ unveils amplification as the main alteration for this gene correlating with increased mRNA expression levels across all types of cancer through the cBioPortal platform. YWHAZ rises as a promising prognostic factor in PCa, independent from GS, aiding in disease risk stratification.

2021-09-08 | PXD014291 | Pride

Human Prostate Cancer Illumina Infinium Human Methylation450 (HM450K bead array) BeadChip samples (benign vs tumor)

Project description:In order to examine the impact our probe filtering efforts might have on the analysis of real-world primary data, we analyzed clinical prostate cancer specimens. This included profiling of four prostate tumour tissue samples and four benign prostate tissues using the Illumina Infinium Human Methylation450 (HM450K bead array) BeadChip. These samples were used to explore the effects on analysis with and without a probe filtering. Four tumour samples containing Gleason 6 cancer and four benign samples from other prostate glands containing Gleason 6 cancer were selected for study. Tissue samples were cryosectioned for histopathological assessment. Genomic DNA was extracted from the homogenized samples using the Allprep Micro Kit (Qiagen, CA, USA) following manufacturer’s instructions and bisulfite converted using the Zymo EZ DNA Methylation kit (Zymo Research Corporation, CA, USA). The resulting libraries were hybridized onto the Illumina HumanMethylation450 (HM450K bead array) BeadChip. Raw intensity data was generated using an iScan microarray reader (Illumina).

2014-12-23 | E-GEOD-47915 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data